Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Diphenhydramine Hydrochloride Tablets 50 mg, Paracetamol 500mg Tablets, Ocrevus 300 mg concentrate for solution for infusion, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion
Hoffmann-La Roche
Relapsing-Remitting Multiple Sclerosis (RRMS)
1 trial -
E7386, Doxorubicin EBEWE 2 mg/ml koncentratas infuziniam tirpalui, E7386, Паклитаксел Ебеве 6 mg/ml концентрат за инфузионен разтвор, Paclitaxel Aurobindo 6 mg/ml concentrato per soluzione per infusione, Doxorubicina Aurobindo 2 mg/ml concentrato per soluzione per infusione, LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules
Eisai Co.,
Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor
1 trial -
ENFORTUMAB VEDOTIN , mRNA-4157, Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Merck Sharp and Dohme
Muscle-invasive Urothelial Carcinoma
1 trial -
Entyvio 300 mg powder for concentrate for solution for infusion
Takeda
Ulcerative Colitis or Crohn's Disease
1 trial -
Erbitux 5 mg/mL solution for infusion
Disc Medicine
Unknown primary tumour of the head and neck
1 trial -
Erbitux 5 mg/mL solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, Braftovi 75 mg hard capsules
The George Institute
Metastatic colorectal cancer
1 trial -
Etoposide 20 mg/ml Concentrate for solution for infusion , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion., ADRIBLASTINE 10 mg, poudre pour solution injectable en flacon, Cyclophosphamide Sandoz, 100 mg/mL, koncentrat do sporządzania roztworu do wstrzykiwań / do infuzji
Ningbo Cancer Hospital
Patients with a confirmed diagnosis of ovarian small cell carcinoma.
1 trial -
Etoposide 20 mg/ml Concentrate for Solution for Infusion, Sodium Chloride 0.9% Intravenous Infusion BP, Vincristine Sulfate 1 mg/ml Solution for Injection or Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Human Albumin Baxalta 50 g/l Solution for Infusion, Cyclophosphamide 1000 mg Powder for Solution for Injection or Infusion, Qarziba 4.5 mg/mL concentrate for solution for infusion, Dacarbazine Lipomed 200 mg powder for solu
AXIM BIOTECHNOLOGIES, INC.
Neuroblastoma
1 trial -
FDC Nivolumab + Relatlimab + rHuPH20 Injection, Nivolumab/Relatlimab, OPDIVO 10 mg/mL concentrate for solution for infusion., Nivolumab Subcutaneous
Bristol-Myers Squibb Australia Pty Ltd
Melanoma
1 trial -
FLUOROURACIL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CALCIUM FOLINATE , OXALIPLATIN , -, CALCIUM LEVOFOLINATE , PARACETAMOL , -, -, -, -, Ifinatamab Deruxtecan
Merck Sharp and Dohme
Esophageal squamous cell carcinoma
1 trial -
FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, S241656 film-coated tablet 50mg, Erbitux 5 mg/mL solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion, S241656 film-coated tablet 25mg, Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bugvi 5 mg/ml pulbere pentru dispersie perfuzabilă, Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung,
The George Institute
Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations
1 trial -
FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Fluorouracil Accord 50 mg/ml Injektions-/ Infusionslösung, Fluorouracile AHCL 50 mg/ml, Soluzione per iniezione o infusione, SOTORASIB, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, FLUOROURACILE ACCORD 50 mg/ml, solutio
CERO THERAPEUTICS HOLDINGS, INC.
colorectal cancer
1 trial -
FRUZAQLA 5 mg hard capsules, FLUOROURACIL, FOLINIC ACID, FLUOROURACIL, IRINOTECAN, OXALIPLATIN, Avastin 25 mg/ml concentrate for solution for infusion., FRUZAQLA 1 mg hard capsules
CERO THERAPEUTICS HOLDINGS, INC.
métastatique colorectal cancer
1 trial -
FRUZAQLA 5 mg hard capsules, Tevimbra 100 mg concentrate for solution for infusion, FRUZAQLA 1 mg hard capsules, Lonsurf 15 mg/6.14 mg film-coated tablets, Avastin 25 mg/ml concentrate for solution for infusion.
The George Institute
Metastatic Colorectal Cancer without liver metastases
1 trial -
Felzartamab, Saline Solution Basi 9 mg/ml solution for infusion
Biogen
Treatment of Late Isolated Microvascular Inflammation in Recipients of Kidney Transplants
1 trial -
Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion.
CERO THERAPEUTICS HOLDINGS, INC.
Pleural mesothelioma
1 trial -
Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion.
Disc Medicine
Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).
1 trial -
Fibromun, Dacarbazine medac 1000 mg, powder for solution for infusion
Philogen S.p.A.
Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens.
1 trial -
Fludarabina Accord 25 mg/ml concentrado para solución inyectable y para perfusión., HSP-CAR30, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, RoActemra 20 mg/mL concentrate for solution for infusion, Genoxal 200 mg polvo para solución inyectable y para perfusión
The George Institute
Refractary or relapse non-Hodgkin T CD30+ lymphoma., Refractary or relapse Hodgkin T CD30+ lymphoma
1 trial -
Fludarabine Teva 25 mg/ml solution à diluer pour injection ou perfusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, LN-145, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cyclophosphamide Injection 1 g., Fludarabine 50mg Powder For Solution For Injection Or Infusion, Endoxan, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, Fludarabinefosfaat – PCH 25 mg/ml, concentraat voor oplossing voor injectie/infusie, FLUDARAB
Iovance Biotherapeutics B.V.
Metastatic Non-Small-Cell Lung Cancer
1 trial -
Fluorouracil 50mg/ml Injection., FOLINIC ACID, Eftozanermin alfa, Telisotuzumab adizutecan, Oxaliplatin 5 mg/ml concentrate for solution for infusion
AbbVie Deutschland GmbH & Co. KG
Adenocarcinoma of the gastroesophageal junction
1 trial -
Fluorouracil Injection 25 mg/ml, solution for injection, Oncofolic 50 mg/ml, Injektions-/Infusionslösung, Irinotecan Hydrochloride 20 mg/mL concentrate for solution for infusion
Wuhan Createrna Science and Technology Co., Ltd
Metastatic Colorectal Cancer
1 trial -
Fluorouracile AHCL 50 mg/ml, Soluzione per iniezione o infusione, Oxaliplatino Accord 5 mg/ml concentrato per soluzione per infusione, LEVOFOLENE 175 mg polvere per soluzione per infusione
Fondazione Telethon ETS
colorectal cancer
1 trial -
Futibatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Taiho Pharma Netherlands B.V.
Advanced or Metastatic Urothelial Carcinoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources